Scholarlink

Purpose <p>To review the mechanistic rationale and recent Phase 3 clinical trial data for baxdrostat, a selective aldosterone synthase inhibitor, in the management of treatment-resistant hypertension.</p> Methods <p>We evaluated efficacy and safety data from the Phase 3 BaxHTN (<i>N</i> = 794) and Bax24 (<i>N</i> = 217) trials, along with a recent systematic review and meta-analysis of aldosterone synthase inhibitors.</p> Results <p>In BaxHTN, baxdrostat 2&#xa0;mg reduced seated systolic blood pressure by -15.7 mmHg (placebo-adjusted − 9.8 mmHg; <i>P</i> &lt; 0.001). In Bax24, 24-hour ambulatory systolic blood pressure decreased by -16.6 mmHg (placebo-adjusted − 14.0 mmHg; <i>P</i> &lt; 0.001). Hyperkalemia (&gt; 5.5 mmol/L) occurred in approximately 12% of baxdrostat-treated patients versus 3% with placebo, with low discontinuation rates (approximately 2%). No cortisol suppression or adrenal insufficiency was observed.</p> Conclusion <p>Baxdrostat has demonstrated among the largest ambulatory blood pressure reductions reported in contemporary treatment-resistant hypertension trials. With FDA Priority Review underway (PDUFA Q2 2026), this first-in-class agent represents a potential therapeutic advancement for patients inadequately controlled on existing regimens.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Baxdrostat and Aldosterone Synthase Inhibitors: A New Class for Treatment-resistant Hypertension

  • 期刊论文

  • 发表日期：

    2026年5月13日

查看全文
  • Ahmar Jan Qureshi,
  • Muhammad Riyyan Tariq Tagga,
  • Abdul Qayum Khan

摘要

Purpose

To review the mechanistic rationale and recent Phase 3 clinical trial data for baxdrostat, a selective aldosterone synthase inhibitor, in the management of treatment-resistant hypertension.

Methods

We evaluated efficacy and safety data from the Phase 3 BaxHTN (N = 794) and Bax24 (N = 217) trials, along with a recent systematic review and meta-analysis of aldosterone synthase inhibitors.

Results

In BaxHTN, baxdrostat 2 mg reduced seated systolic blood pressure by -15.7 mmHg (placebo-adjusted − 9.8 mmHg; P < 0.001). In Bax24, 24-hour ambulatory systolic blood pressure decreased by -16.6 mmHg (placebo-adjusted − 14.0 mmHg; P < 0.001). Hyperkalemia (> 5.5 mmol/L) occurred in approximately 12% of baxdrostat-treated patients versus 3% with placebo, with low discontinuation rates (approximately 2%). No cortisol suppression or adrenal insufficiency was observed.

Conclusion

Baxdrostat has demonstrated among the largest ambulatory blood pressure reductions reported in contemporary treatment-resistant hypertension trials. With FDA Priority Review underway (PDUFA Q2 2026), this first-in-class agent represents a potential therapeutic advancement for patients inadequately controlled on existing regimens.